GILEAD SCIENCES, INC. Equity Securities, FV-NI, Unrealized Gain
GILEAD SCIENCES, INC. (GILD) reported Equity Securities, FV-NI, Unrealized Gain of $69.00 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-08-04.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGain · last filed 2023-08-04
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2023-06-30 was $69.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2020-06-30 was $201.00M, a 252.63% increase year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2019-12-31 was $888.00M.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for the quarter ending 2019-09-30 was $58.00M, a 65.48% decline year-over-year.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for fiscal 2019 was $1.20B, a 943.48% increase from fiscal 2018.
- GILEAD SCIENCES, INC. equity securities, fv-ni, unrealized gain for fiscal 2018 was $115.00M.
| Period end | Equity Securities, FV-NI, Unrealized Gain 3 month | Equity Securities, FV-NI, Unrealized Gain 6 month | Equity Securities, FV-NI, Unrealized Gain 9 month | Equity Securities, FV-NI, Unrealized Gain 12 month |
|---|---|---|---|---|
| 2023-06-30 | $69.00M 10-Q · filed 2023-08-04 | |||
| 2020-06-30 | $201.00M 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | $888.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $946.00M derived: sum of 2 quarters · filed 2022-02-23 | $1.00B derived: sum of 3 quarters · filed 2022-02-23 | $1.20B 10-K · filed 2022-02-23 |
| 2019-09-30 | $58.00M 10-Q · filed 2020-11-04 | $115.00M derived: sum of 2 quarters · filed 2020-11-04 | $312.00M 10-Q · filed 2020-11-04 | $278.00M derived: sum of 4 quarters · filed 2020-11-04 |
| 2019-06-30 | $57.00M 10-Q · filed 2020-08-06 | $254.00M 10-Q · filed 2020-08-06 | $220.00M derived: sum of 3 quarters · filed 2020-08-06 | $388.00M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $197.00M 10-Q · filed 2020-05-06 | $163.00M derived: sum of 2 quarters · filed 2020-05-06 | $331.00M derived: sum of 3 quarters · filed 2020-05-06 | |
| 2018-12-31 | -$34.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $134.00M derived: sum of 2 quarters · filed 2020-02-25 | $115.00M 10-K · filed 2020-02-25 | |
| 2018-09-30 | $168.00M 10-Q · filed 2019-11-05 | $149.00M 10-Q · filed 2019-11-05 | ||
| 2018-03-31 | $45.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |